Abstract 3017: Using a pharmacodynamic biomarker led approach to explore and quantify the combination effect of savolitinib and osimertinib in the LG1208 NSCLC PDX model
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Research"
DOI: 10.1158/1538-7445.am2020-3017
Abstract: MET-amplification has been identified as a resistance mechanism in >5% of patients with non-small cell lung cancer (NSCLC) and 25% of those that progress on 1st/2nd or 3rd generation epidermal growth factor receptor-tyrosine kinase inhibitors… read more here.
Keywords: savolitinib; combination; effect; model ... See more keywords
Abstract LB294: Baseline and on-treatment plasma-based genomics as a predictor of outcome in SAVANNAH: Savolitinib + osimertinib in EGFRm MET overexpressed/amplified NSCLC post-osimertinib
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-lb294
Abstract: Savolitinib, an oral, potent, and highly selective MET-TKI, in combination with osimertinib, a 3rd-generation, irreversible, oral EGFR-TKI, may overcome common acquired MET-driven resistance following osimertinib treatment. The ongoing Ph2 SAVANNAH (NCT03778229) study is investigating this… read more here.
Keywords: plasma; post osimertinib; savolitinib osimertinib; plasma egfrm ... See more keywords